1. Home
  2. EQBK vs REPL Comparison

EQBK vs REPL Comparison

Compare EQBK & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQBK
  • REPL
  • Stock Information
  • Founded
  • EQBK 2002
  • REPL 2015
  • Country
  • EQBK United States
  • REPL United States
  • Employees
  • EQBK N/A
  • REPL N/A
  • Industry
  • EQBK Major Banks
  • REPL Biotechnology: Pharmaceutical Preparations
  • Sector
  • EQBK Finance
  • REPL Health Care
  • Exchange
  • EQBK Nasdaq
  • REPL Nasdaq
  • Market Cap
  • EQBK 763.9M
  • REPL 780.3M
  • IPO Year
  • EQBK 2015
  • REPL 2018
  • Fundamental
  • Price
  • EQBK $42.99
  • REPL $13.98
  • Analyst Decision
  • EQBK Hold
  • REPL Strong Buy
  • Analyst Count
  • EQBK 5
  • REPL 6
  • Target Price
  • EQBK $45.60
  • REPL $19.83
  • AVG Volume (30 Days)
  • EQBK 64.1K
  • REPL 610.9K
  • Earning Date
  • EQBK 04-15-2025
  • REPL 02-12-2025
  • Dividend Yield
  • EQBK 1.37%
  • REPL N/A
  • EPS Growth
  • EQBK 700.00
  • REPL N/A
  • EPS
  • EQBK 4.00
  • REPL N/A
  • Revenue
  • EQBK $220,307,000.00
  • REPL N/A
  • Revenue This Year
  • EQBK N/A
  • REPL N/A
  • Revenue Next Year
  • EQBK $6.39
  • REPL $1,065.54
  • P/E Ratio
  • EQBK $10.89
  • REPL N/A
  • Revenue Growth
  • EQBK 59.51
  • REPL N/A
  • 52 Week Low
  • EQBK $30.44
  • REPL $4.92
  • 52 Week High
  • EQBK $50.85
  • REPL $17.00
  • Technical
  • Relative Strength Index (RSI)
  • EQBK 45.18
  • REPL 55.54
  • Support Level
  • EQBK $43.01
  • REPL $13.40
  • Resistance Level
  • EQBK $44.03
  • REPL $14.59
  • Average True Range (ATR)
  • EQBK 0.96
  • REPL 0.84
  • MACD
  • EQBK -0.07
  • REPL -0.02
  • Stochastic Oscillator
  • EQBK 31.97
  • REPL 66.52

About EQBK Equity Bancshares Inc.

Equity Bancshares Inc is a bank holding company. The company's operation involves the delivery of loan and deposit products to customers. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Share on Social Networks: